Immunocore Holdings (IMCR) Long-Term Deferred Tax (2019 - 2025)
Immunocore Holdings (IMCR) posted Long-Term Deferred Tax of $14.3 million for Q3 2025, up 1.82% sequentially from $14.1 million in Q2 2025, and up 13.19% YoY from $12.7 million in Q3 2024.
Analysis
Immunocore Holdings (IMCR) Long-Term Deferred Tax (2019 - 2025) Analysis & Trends
Immunocore Holdings has reported Long-Term Deferred Tax for 7 years, with the latest figure at $14.3 million in Q3 2025.
- Quarterly Long-Term Deferred Tax rose 13.19% year-over-year to $14.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $14.3 million (up 13.19% YoY) and the FY2024 annual result came in at $14.8 million, up 34.79% from the prior year.
- Long-Term Deferred Tax advanced to $14.3 million in Q3 2025 per IMCR's latest filing, from $14.1 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $14.8 million in Q4 2024 and troughed at $3.5 million in Q4 2021.
- A 5-year average of $10.1 million and a median of $10.9 million in 2023 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2023 and 2025: Long-Term Deferred Tax jumped 120.64% in 2023, then advanced 13.19% in 2025.
- Over 5 years, Long-Term Deferred Tax stood at $3.5 million in 2021, then surged by 43.27% to $5.0 million in 2022, then surged by 120.64% to $11.0 million in 2023, then soared by 34.79% to $14.8 million in 2024, then fell by 3.09% to $14.3 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $14.3 million, $14.1 million, and $14.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 14.33 Mn |
| Jun 30, 2025 | 14.08 Mn |
| Mar 31, 2025 | 14.36 Mn |
| Dec 31, 2024 | 14.79 Mn |
| Sep 30, 2024 | 12.66 Mn |
| Jun 30, 2024 | 10.11 Mn |
| Mar 31, 2024 | 10.80 Mn |
| Dec 31, 2023 | 10.97 Mn |
| Jun 30, 2023 | 5.56 Mn |
| Dec 31, 2022 | 4.97 Mn |
| Sep 30, 2022 | 4.55 Mn |
| Dec 31, 2021 | 3.47 Mn |
| Dec 31, 2020 | 2.94 Mn |
| Dec 31, 2019 | 1.94 Mn |